1988
DOI: 10.1002/mus.880110602
|View full text |Cite
|
Sign up to set email alerts
|

Normal myoblast injections provide genetic treatment for murine dystrophy

Abstract: A treatment has been developed to alleviate muscle weakness in murine dystrophy. Cultured myoblasts from genetically normal mouse embryos were injected into the right soleus of 20-day-old normal or dystrophic mice. Hosts and donors were immunocompatible but exhibited different genotype markers. Donor cells produced GPl-1CC. Host cells produced GPl-1BB. When compared with contralateral controls 6 months postoperatively, test dystrophic solei exhibited greater cross-sectional area, total fiber number, wet weight… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
33
1
1

Year Published

1990
1990
2012
2012

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 114 publications
(35 citation statements)
references
References 39 publications
0
33
1
1
Order By: Relevance
“…If the contractile properties of dystrophic muscle fibres are not compromised by the lack of dystrophin as we have shown, but rather non-specifically by the degeneration/regeneration processes, then procedures aimed at halting or reversing these deleterious cycles may represent sufficient treatment strategy. For example, the implantation of normal myoblasts into dystrophic muscle results in mosaic fibres possessing normal and dystrophic nuclei (Law, Goodwin & Wang, 1988;Karpati, Pouliot, Carpenter & Holland, 1989;Partridge, Morgan, Coulton, Hoffman & Kunkel, 1989;Huard, Labrecque, Dansareau, Robitaille & Tremblay, 1991), which can express dystrophin, and potentially reduce any susceptibility of the muscle fibre membrane to suffer stressinduced injury. If such treatments are carried out before significant deterioration in muscle function is detected then it is apparent from the results presented here, and in our related studies of muscle function in other dystrophies (Fink et al 1986(Fink et al , 1990Head et al 1990) that muscle function will be preserved at near-normal levels.…”
Section: Discussionmentioning
confidence: 99%
“…If the contractile properties of dystrophic muscle fibres are not compromised by the lack of dystrophin as we have shown, but rather non-specifically by the degeneration/regeneration processes, then procedures aimed at halting or reversing these deleterious cycles may represent sufficient treatment strategy. For example, the implantation of normal myoblasts into dystrophic muscle results in mosaic fibres possessing normal and dystrophic nuclei (Law, Goodwin & Wang, 1988;Karpati, Pouliot, Carpenter & Holland, 1989;Partridge, Morgan, Coulton, Hoffman & Kunkel, 1989;Huard, Labrecque, Dansareau, Robitaille & Tremblay, 1991), which can express dystrophin, and potentially reduce any susceptibility of the muscle fibre membrane to suffer stressinduced injury. If such treatments are carried out before significant deterioration in muscle function is detected then it is apparent from the results presented here, and in our related studies of muscle function in other dystrophies (Fink et al 1986(Fink et al , 1990Head et al 1990) that muscle function will be preserved at near-normal levels.…”
Section: Discussionmentioning
confidence: 99%
“…The residual CAT activity observed in pIEB217CAT-transfected myotubes may be due to a pseudo-TATA box (positions -147 to -152 in Fig. 5 (39,59).…”
Section: Methodsmentioning
confidence: 99%
“…Among other therapeutic approaches, over the past two decades there has been considerable experimentation with cell-based therapy as a means to treat DMD (Law et al, 1988;Karpati et al, 1989;Partridge et al, 1989). This strategy involves transplanting cells that produce a functional copy of dystrophin into an affected individual so that the donor cells can provide gene products normally absent or non-functional in the recipient.…”
Section: Introductionmentioning
confidence: 99%